# SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China

Source: https://onco.cc/key-papers/paper-nct04665856-j-thorac-oncol-2026/  
OnCo record `paper-nct04665856-j-thorac-oncol-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Published report from the SKYSCRAPER-02C trial registered as NCT04665856, in Journal of Thoracic Oncology (2026), chosen as the most cited paper whose own text cites the registry id.

## Summary

Introduction: Tiragolumab may synergize with other immunotherapies to enhance antitumor immune responses. We report efficacy, safety, and biomarker findings from SKYSCRAPER-02C (NCT04665856), comparing tiragolumab plus atezolizumab plus carboplatin and etoposide (CE; experimental arm) with atezolizumab plus CE (control arm) in patients with untreated extensive-stage SCLC (ES-SCLC) in China.

Methods: Patients were randomized (1:1) to tiragolumab 600 mg or placebo, plus atezolizumab 1200 mg and CE (four cycles), then maintenance tiragolumab or placebo plus atezolizumab. Primary end points were investigator-assessed progression-free survival (PFS) and overall survival (OS) in patients without history or presence of brain metastases at baseline (primary analysis set).

Results: The primary analysis set comprised 54 patients in the experimental arm and 56 in the control arm. Median PFS was 5.6 months (experimental) and 5.4 months (control; unstratified hazard ratio = 0.65, 95% confidence interval: 0.43‒0.97; median follow-up 26.7 months); median OS was 18.7 and 13.5 months, respectively (unstratified hazard ratio 0.89, 95% confidence interval: 0.56‒1.40). The biomarker-evaluable population comprised 69 patients with immunohistochemistry data and 66 with RNA sequencing data. RNA sequencing survival analysis found that patients with non-negative matrix factorization 3 (SCLC-inflamed-neuroendocrine) or non-negative matrix factorization 4 (SCLC-inflamed-non-neuroendocrine) molecular subtypes, and those with high T-effector and tumor-associated macrophage immune signatures, benefited from tiragolumab plus atezolizumab plus CE treatment. Tiragolumab was well tolerated, with no new safety signals.

Conclusions: Although results from the global SKYSCRAPER-02 study were not statistically significant, numerical improvements in PFS and OS were observed with tiragolumab plus atezolizumab plus CE versus atezolizumab plus CE in Chinese patients with ES-SCLC. Biomarker analysis identified immune-inflamed signatures that may guide future tyrosine-based inhibitory motif domain-based strategies.

Indexed on Europe PMC as PubMed record 41950998 (DOI 10.1016/j.jtho.2026.103713). Its abstract cites the registry id NCT04665856, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Journal of Thoracic Oncology
- Year: 2026
- DOI: 10.1016/j.jtho.2026.103713
- Authors: Lu S, Fang J, Yu Y, et al.
- What it means: This is the paper Europe PMC returns for registry id NCT04665856 with the most citations, so it is the natural first reading for anyone following the SKYSCRAPER-02C trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.

## Sources

- J Thorac Oncol 2026: https://doi.org/10.1016/j.jtho.2026.103713
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41950998/
- Europe PMC: https://europepmc.org/article/MED/41950998
- ClinicalTrials.gov NCT04665856: https://clinicaltrials.gov/study/NCT04665856

## Connected records

- trials: [Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04665856/)
- journals: [Journal of Thoracic Oncology](https://onco.cc/journals/journal-of-thoracic-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-nct04665856-j-thorac-oncol-2026.json